Inside SoCal: Learning at Any Age (6/15)
Tuition-free learning to jump-start a new career is the goal of LAUSD's DACE program for adults – at any age. Students share how it's changed their lives for the better.
LEARNING AT ANY AGE Sponsored by LAUSD Division of Adult and Career Education
Life can get in the way at times, but it's never too late to learn or to change your future. Through LAUSD's DACE program (Division of Adult and Career Education), you can get your GED or learn a brand new skill set in a shorter time frame so you can jumpstart your new career. Tuition-free classes are a key component of this program, as are the diverse classes available – healthcare, tech, trades, and more. It's also designed for people juggling work, family, and everything else. They have campuses all over LA, as well as online options. Learn more at https://adulted.lausd.org. It's never too late to pursue your dreams.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / ACCESS Newswire / June 15, 2025 / Adolore BioTherapeutics ('Adolore' or the 'Company'), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, 'Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1,' in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, 'Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102.' The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project,' 'will,' 'should,' 'may,' 'plan,' 'intend,' 'assume' and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542 [email protected] SOURCE: Adolore Biotherapeutics, Inc. press release
Yahoo
an hour ago
- Yahoo
Experts Say This Type Of Exercise Is The 'Fountain Of Youth'— Especially If You're Over 50
Aging gracefully isn't just about staying active; it's about choosing the right kind of activity to support your health. Resistance training (such as bodyweight, free weight, and resistance band exercises) is one of the best ways to counter the effects of aging, helping you build up muscle to support daily activities and prevent conditions like osteopenia and osteoporosis that can lead to bone fractures. And even if you've never lifted a weight before, it's never too late to start. 'Weight training is the fountain of youth,' says Abby Bales, PT, DPT, CSCS, founder of Reform Physical Therapy. 'Not only does it help increase and maintain bone density to prevent fractures, but the muscle mass that weight training builds also helps to regulate our blood sugar and metabolism.' Weight lifting can even improve balance and coordination, decreasing the frequency, severity, and likelihood of falls. On top of the physical benefits, resistance training has shown promise in staving off neurological conditions like Alzheimer's and dementia, according to a 2023 study published in Frontiers in Neuroscience, making it a multi-benefit tool for aging well. You can think of lifting weights as your body's best tool to promote resilience, energy, and independence through the aging process. Starting with small, manageable steps—such as incorporating resistance bands or light weights (at first) into your routine—can help you gain confidence and momentum while reaping the long-term benefits. Remember: Building a strength training routine doesn't have to be complicated—it just needs to be consistent. 'Start small, build gradually, and stick with it,' says Bales. She recommends starting with two or three sessions per week. Try rotating between upper body, lower body, and core exercises to keep things balanced. Progress takes time, so be patient. 'Results usually show in six to eight weeks,' Bales explains. The key is to keep showing up and enjoy the process—your future self will thank you. Need some inspiration to get started? Weight lifting later in life doesn't come without its fair share of challenges, but the rewards far outweigh the hurdles. Take it from these inspiring women, who spoke with WH previously about their later-in-life strength training journeys: Marilynn Larkin says not to let fear or self-consciousness hold you back. 'Feel your fear, then go through it,' she previously told WH. Following a cancer diagnosis, lifting weights became a way to push through her fears and embrace all that her body was capable of. '[Weight lifting] is all about allowing your body to reach its full potential and accepting it as it is.' Ginny MacColl recommends starting with a small yet challenging goal and celebrating each milestone—no matter how small, focusing on progress, not perfection. 'Little by little, these small steps lead to big changes,' she previously told WH, after becoming the oldest woman to complete an obstacle on American Ninja Warrior and breaking a Guinness World Record as a result. 'Instead of letting negativity and thoughts like 'I can't' creep in, I focus on getting stronger, physically and mentally. It works.' Michelle Alber says don't wait. After just 18 months of training focused on progressive overload (gradually increasing the weight and intensity of her workouts) and working with a coach to ensure her routine was safe and effective, she reversed her osteoporosis. 'There is never a 'perfect' time to start or a 'right' time to do anything,' she previously told WH. 'Was it hard to make major lifestyle changes at 65? Yes! But it's about choosing your 'hard' and taking control of your life.' You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
CBS News
2 hours ago
- CBS News
Alex's Lemonade Stand Foundation celebrates 25 years of impact, inspiration benefitting children with cancer
It was 25 years ago that Alex Scott held her first lemonade stand. Today, the foundation in her name has raised more than $300,000,000. The little lemonade girl has had quite an impact on the world and children with cancer, kids like Philip Steigerwald. "I really thought that he was going to die, and I had to come to terms with that," said Wendy Steigerwald, Philip's mother. But Philip Steigerwald is alive because of Alex's Lemonade Stand Foundation. Right before his third birthday, he was diagnosed with neuroblastoma –the same cancer Alex Scott had. CBS Philadelphia "I remember when he was getting the chemo, I was meeting with somebody about you know, all the troubles that we were having, and I remember saying to her, 'We could have had a good life,' and she's like, 'Why do you say that?' I said, 'Well, cause he's dying, he'll be dead,'" Wendy Steigerwald said. After grueling treatments, doctors told the Steigerwalds that there was nothing more they could do. That is, until they learned of a clinical trial at the Children's Hospital of Philadelphia, partly funded by Alex's Lemonade Stand Foundation. "It's been a game changer. Kids who were destined to die are alive today," Dr. Yael Mossé, with the Children's Hospital of Philadelphia. "Every morning he would take a pill, that's all he did, and it worked, it worked. I mean, it was a miracle," Wendy Steigerwald said. Philip Steigerwald is not the only child alive today because of Alex and the foundation created in her name. CBS Philadelphia Brynn was part of a clinical trial in Georgia, partially funded by Alex's Lemonade Stand Foundation. She gets scans every six months, and a member of her family said things have been amazing since they ended the trial. Lincoln and Abbie were in that trial. Lincoln is cancer-free! Plus, Abbie's tumor is stable, and she has a Master's degree and volunteers at a camp for children with cancer. CBS Philadelphia Those clinical trials, those miracles started with Alex Scott and her idea for a front-yard lemonade stand. She wanted to help all kids with cancer, not just neuroblastoma. "I thought we might find a cure for her," said Liz Scott, Alex's mother. "We knew a lot of kids with neuroblastoma, and I felt like it was something that we needed to put all the funding into. But Alex very smartly told me that that was selfish and that all kids want their cancer to go away." "If Alex didn't push us to fund all types of childhood cancer research, we wouldn't be where we are today," Jay Scott said. "Because we would be a neuroblastoma organization. We would be much smaller. We would have been unable to help as many kids as we've been able to help." CBS Philadelphia The Alex's Lemonade Stand Foundation has funded 1,500 medical research grants at 150 institutions, and there are more than 240 ongoing clinical trials that are funded by them each year. "If you're doing pediatric cancer research, you come to [the] Alex Lemonade Stand Foundation. We couldn't do our work without this kind of support," said Dr. Leonard Zon with Boston Children's Hospital. Twenty-five years of making a difference, better treatments and safer cures. Twenty-five years of offering hope. "That's where your hope comes from," Liz Scott said. "That there's going to be something new in the pipeline that your child is going to receive that's going to make their cancer go away. It didn't happen for Alex, but the fact that it's happening for other kids now because of Alex is beyond anything I can express what that means." "Wendy would always say 'Show me one kid that survived this,' and that's what – we didn't have any hope and now Philip, is that hope for parents that are going through it now," Philip Steigerwald's father said. CBS Philadelphia
